Remdesivir Completed Phase 3 Trials for Coronavirus Disease 2019 (COVID‑19) Treatment

Back to Remdesivir
IndicationsStatusPurposePhase
CompletedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT05185284Randomized Multicenter Study on the Efficacy and Safety of Favipiravir for Parenteral Administration Compared to Standard of Care in Hospitalized Patients With COVID-19
NCT04843761ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19
NCT04853901Remdesivir Efficacy In Management Of COVID-19 Patients
NCT04640168Adaptive COVID-19 Treatment Trial 4 (ACTT-4)
NCT04593940Immune Modulators for Treating COVID-19
NCT04492475Adaptive COVID-19 Treatment Trial 3 (ACTT-3)
NCT04401579Adaptive COVID-19 Treatment Trial 2 (ACTT-2)
NCT04292730Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment
NCT04292899Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)
NCT04280705Adaptive COVID-19 Treatment Trial (ACTT)